Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.
Neurol Neuroimmunol NeuroinflammJul 13, 2026 (epub)
Sean J Pittock, Michael H Barnett, Jeffrey L Bennett et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III randomized controlled trial evaluated the long-term efficacy and safety of ravulizumab in adults with AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Among 55 patients completing the long-term extension, no relapses occurred during a median follow-up of over 3 years, demonstrating a 98.9% relative reduction in relapse risk compared to placebo.
Key findings
- No patient receiving ravulizumab had an adjudicated on-trial relapse during the study period.
- The relative reduction in risk of relapse vs placebo was 98.9% (95% CI 91.8-100; p < 0.0001).
- Treatment-emergent adverse events were reported in 94.8% of patients, with most being grade 1.
Why it matters
The findings support the use of ravulizumab as a highly effective long-term treatment option for patients with AQP4-Ab+ NMOSD, significantly reducing the risk of clinical relapses.